Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023

Vabysmo data suggest rapid and robust drying of retinal fluid in patients withneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaReal-world studies ofVabysmo demonstrate ability to extend treatment intervals in the first four months while maintaining visual acuityClinical data on an investigational anti-interleukin-6 treatment inuveitic macular edema will be presented for the first timeBasel, 13 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data for its approved and investigational medicines will be highlighted in 30 abstracts at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held from 23-27 April 2023 in New Orleans, United States. The abstracts showcase the strength and breadth of Roche ’s Ophthalmology portfolio, including post-hoc data from phase III Vabysmo® (faricimab) studies that support its benefit in drying retinal fluid in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME).1-3 Real-world data on Vabysmo treatment patterns and outcomes will be presented, as well as approaches to personalised healthcare that include the use of artificial intelligence (AI) modelling to predict retinal disease progression.4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news